Kev Ntsuam Xyuas Tag Nrho Ntawm MRNA Drug Manufacturing Txheej Txheem: Yuav Ua Li Cas TFF Technology daws Cov Kev Sib Tw Purification
Nyob rau hauv xyoo tas los no, mRNA thev naus laus zis tau ua tiav qhov kev vam meej hauv biopharmaceutical teb, ua kom pom qhov muaj peev xwm siv tau zoo, tshwj xeeb hauv cov tshuaj tiv thaiv thiab kho noob. Kev vam meej ntawm cov tshuaj tiv thaiv mRNA tsis tau tsuas yog muab cov kev daws teeb meem tshiab rau kev tiv thaiv thiab tswj cov kab mob sib kis, tab sis kuj tau ua rau muaj kev nce qib hauv kev tiv thaiv kab mob qog noj ntshav thiab tshuaj kho tus kheej. Raws li cov chav kawm tshiab ntawm cov khoom siv kho mob, loj- nplai mRNA kev tsim khoom yog qhov nyuaj heev, suav nrog kev tswj hwm RNA ruaj khov, tshem tawm cov enzymes seem thiab cov tshuaj tiv thaiv los ntawm -cov khoom lag luam, tsis sib pauv, thiab kev ua tiav ntawm siab - purity rov qab tus nqi, tag nrho cov uas yuav tsum tau tsim cov thev naus laus zis{5} kev tswj hwm.
Kev tsim cov tshuaj tiv thaiv mRNA lossis kev kho mob feem ntau yog muab faib ua peb theem: kev npaj ntawm plasmid DNA bulk tov, kev npaj ntawm mRNA bulk tov, thiab kev npaj ntawm mRNA-LNP cov khoom siv tshuaj.
mRNA Drug Manufacturing Process Flowchart
Tangential flow filtration (TFF), raws li ib tug zoo-tsim membrane sib cais tshuab, yog dav siv nyob rau hauv mRNA manufacturing vim nws siab -kev ua tau zoo molecular sieving muaj peev xwm, controllable buffer exchange, thiab tsawg shear stress yam ntxwv. Raws li kev tsim qauv membrane, TFF configurations muaj xws li tiaj-cov ntawv cassettes thiab hollow- fiber modules. Tsis tas li ntawd, lub siab- tsav cov membrane sib cais hauv TFF tuaj yeem muab faib ua microfiltration (MF), ultrafiltration (UF), nanofiltration (NF), thiab thim rov qab osmosis (RO) raws li daim nyias nyias qhov pore loj, nrog kev nce qib ntxiv.
TFF ua lub luag haujlwm tseem ceeb hauv ntau theem ntawm mRNA kev tsim tshuaj, suav nrog kev npaj ntawm plasmid DNA bulk, mRNA bulk ntau lawm, thiab qhov kawg formulation ntawm mRNA-LNP cov khoom siv tshuaj. Los ntawm kev xaiv tsim nyog ntawm hom membrane, qhov hnyav molecular txiav-tawm (MWCO), thiab cov khoom siv membrane, TFF ua kom muaj txiaj ntsig tshem tawm cov tshuaj tiv thaiv los ntawm - cov khoom thiab qis -molecular- hnyav impurities, thaum tseem ua kom yooj yim tsis sib pauv thiab concentration ob qho tib si ua ntej thiab tom qab LNP encapsulation. Qhov no txhim kho RNA purity, stability, thiab tag nrho cov txheej txheem scalability.
Tsis tas li ntawd, qhov kev ua tau zoo ntawm tangential flow filtration yog cuam tshuam los ntawm cov txheej txheem kev teeb tsa xws li lub twj tso kua mis thiab lub raj tsim, nrog rau cov txheej txheem tseem ceeb suav nrog kev hloov pauv siab (TMP), shear stress, thiab pom flux. Cov yam tseem ceeb no yuav tsum tau ua tib zoo xaiv thiab ua kom zoo raws li cov yam ntxwv ntawm cov khoom lag luam, tshwj xeeb tshaj yog rau kev ntxhov siab- cov khoom lag luam rhiab heev xws li mRNA–LNP, uas muaj kev cuam tshuam rau cov khoom siv sab nraud thaum ua haujlwm.
Purification ntawm plasmid DNA
Kev npaj ntawm plasmid DNA Tshuag cov tshuaj yog tsim los ntawm cov qauv tsim ntawm cov qauv sau ntawv. Cov txheej txheem npaj feem ntau koom nrog plasmid DNA amplification, txawm hais tias PCR amplification tuaj yeem siv tau. Siv DNA amplification ua piv txwv, engineeredE. colifeem ntau yog siv rau fermentation -raws li amplification. Cov txheej txheem purification downstream feem ntau suav nrog kev sau ntawm tes, lysis thiab qhia meej, kev sib xyaw thiab tsis sib pauv, tsis muaj qhov pom, linearization, thiab chromatographic purification. Nyob rau hauv kev lag luam chaw, tas mus li -flow centrifugation feem ntau yog siv rau kev sau ntawm tes, tab sis nws tsim muaj zog shear zog. Hollow fiber systems, nrog rau lawv txoj kev qhib thiab qis shear, yog qhov tsim nyog rau kev coj cov qauv nrog cov ntsiab lus siab, siab viscosity, los yog shear rhiab heev, xws li plasmid DNA. Tom qab sau, cov hlwb raug rau siab -siab homogenization, ultrasonication, los yog alkaline lysis, ua raws li kev qhia ua ntej los ntawm qhov tob pom.
Txhawm rau pab txhawb cov chromatography tom ntej, tangential flow filtration (TFF) siv cov membrane cassettes los yog hollow fiber kem nrog molecular hnyav txiav -offs ntawm 30 kDa, 100 kDa, los yog 300 kDa feem ntau ua hauj lwm ua ntej rau concentration thiab tsis pauv. Qhov no txo cov qauv ntim thaum ib txhij tshem tawm qee qhov impurities xws li RNA, tus tswv tsev cell proteins (HCP), thiab host cell DNA fragments (HCD). Chromatography ua haujlwm ua cov kauj ruam ua kom huv si. Feem ntau, anion pauv chromatography (AEX) yog ua ke nrog hydrophobic interaction chromatography (HIC) kom zoo tshem tawm impurities thiab enrich heev bioactive supercoiled plasmid DNA, yog li no ho txhim kho plasmid purity.
Tom qab kev ua kom huv, cov plasmid raug rau TFF dua kom mloog zoo rau cov kev daws teeb meem rau lub hom phiaj concentration (feem ntau yog 0.5-2 mg / mL) thiab ua kev lim ntshav nrog qhov kawg cia tsis. Cov kauj ruam no tshem tawm cov ntsev seem thiab cov kuab tshuaj organic los ntawm cov txheej txheem, kom ntseeg tau tias cov txheej txheem tsis ua tau raws li qhov yuav tsum tau ua rau cov dej hauv vitro transcription (IVT) cov tshuaj tiv thaiv.
Kev lim dej hauv vitro transcribed (IVT) mRNA
In vitro transcription (IVT) and modification are the key processes for the preparation of mRNA stock solutions. During IVT mRNA production, a combination of tangential flow filtration (TFF1) – chromatography – tangential flow filtration (TFF2) is employed. This strategy ensures efficient and high-quality purification of mRNA, providing critical support for vaccine manufacturing.
Tom qab qhov kev hloov pauv thiab kev hloov pauv tau ua tiav lawm, ultrafiltration / diafiltration siv cov membrane cassettes los yog hollow fiber kab nrog molecular hnyav txiav -offs ntawm 30 kDa, 100 kDa, los yog 300 kDa feem ntau ua ntej. Cov kauj ruam no tshem tawm ntau yam txheej txheem-txog impurities los ntawm cov tshuaj tiv thaiv kab mob, xws li RNA polymerase, residual DNA fragments, unreacted NTPs, capping enzymes, ob -stranded RNA (dsRNA), thiab me me - molecule inhibitors, thaum tib lub sij hawm ua kom tsis txhob pauv. Tom qab ib qho tangential flow filtration kauj ruam, feem ntau cov impurities raug tshem tawm zoo, thiab tsuas yog cov khoom seem uas tsis muaj protein ntau yog RNA polymerase.
Tom qab ntawd, ntau cov txheej txheem chromatography tau siv rau kev ua kom huv ntxiv. Cov kev siv feem ntau suav nrog affinity chromatography, loj-exclusion chromatography, ion-pair reverse-phase chromatography, thiab ion- pauv chromatography. Los ntawm kev sib xyaw ua ke ntawm ultrafiltration thiab sequential chromatography, mRNA ua tiav qib siab ntawm purity.
Txhawm rau ua kom tau raws li kev tsim lossis kev cia khoom, mRNA cov khoom lag luam yog rov qab los yog diluted siv 30 kDa, 100 kDa, lossis 300 kDa membrane cassettes lossis hollow fiber txhua kab kom meej kho lub hom phiaj concentration thiab pauv mus rau qhov kawg formulation tsis. Thaum kawg, tsis muaj menyuam - qib pom yog siv los tswj cov kab mob microbial, ua kom tiav qhov chaw cia ib ntus thiab ntim cov khoom.
Exploration of TFF-related process parameters: Relevant studies have shown that a membrane with a molecular weight cut-off (MWCO) of 100 kDa provides the optimal purification efficiency; the transmembrane pressure (TMP) should not exceed 5 psi; and an mRNA concentration of 1 mg/mL ensures a relatively high permeate flux (>25 HML).
Kev ua kom huv ntawm mRNA-LNP formulations
Lipid nanoparticles (LNPs) tam sim no yog qhov kev kawm dav dav tshaj plaws rau kev kho mRNA. Tam sim no, ntau yam mRNA-LNP formulations nyob rau hauv ntau theem ntawm preclinical thiab kho mob kev loj hlob. LNPs yog cov rhiab heev rau kev tsim khoom. Ntawm cov haujlwm hauv chav tsev uas yuav tsum tau muaj rau mRNA-LNP ntau lawm, concentration thiab tsis sib pauv los ntawm tangential flow filtration (TFF) nrog rau kev ua kom tsis muaj menyuam muaj teeb meem tseem ceeb. Cov kauj ruam no yuav tsum tau ua tib zoo ua kom zoo los xyuas kom meej cov txheej txheem scalability thiab cov khoom zoo, thaum tsis txhob muaj teeb meem xws li membrane fouling thiab tsis raug lim loading.
Tom qab mRNA encapsulation, tangential flow filtration (TFF) yog siv rau purification. Lub hom phiaj ntawm cov kauj ruam no yog tshem tawm mRNA unencapsulated, dawb polymers lossis lipid cov ntaub ntawv, nrog rau cov kuab tshuaj seem ntawm mRNA thiab lipids. Txij li thaum mRNA-LNPs muaj qhov tsis muaj kev ruaj ntseg ntawm chav tsev kub, kev ua kom zoo ntawm cov txheej txheem qis qis, suav nrog TFF, yog qhov tseem ceeb rau kev tswj cov khoom zoo.
Cov lus qhia ua kom zoo tshaj plaws suav nrog: tsim nyog teeb tsa lub siab transmembrane (TMP) thiab tangential txaus tus nqi raws li qhov loj me thiab ruaj khov ntawm mRNA-LNPs kom sib npaug pom kev ua haujlwm zoo thiab kev ntxhov siab particle; xaiv daim nyias nyias los yog hollow fiber kab uas haum molecular hnyav txiav -offs (MWCO, piv txwv li, 100 kDa los yog 300 kDa) kom zoo tshem tawm cov dawb mRNA, impurities, thiab pauv tsis thaum lub sij hawm txo particle adsorption los yog puas; thiab optimizing cov concentration thiab diafiltration ntim kom ntseeg tau zoo tsis pauv mus rau hauv lub hom phiaj formulation thiab tswj qhov kawg particle concentration thiab dispersity.
Tsis tas li ntawd, cov yam ntxwv tseem ceeb (xws li qhov loj me, qhov ntsuas qhov sib txawv ntawm qhov sib txawv [PDI], thiab mRNA encapsulation efficiency) yuav tsum tau saib xyuas zoo thaum lub sij hawm tus txheej txheem, thiab cov kev ntsuas dynamically hloov raws li qhov tiag -cov ntaub ntawv lub sij hawm kom ua tiav ruaj khov, scalable, thiab muaj txiaj ntsig purification thiab formulation ntawm mRNAs {{1}L.
Tsis tas li ntawd, vim qhov tsis ruaj khov ntawm mRNA-LNPs thiab lawv cov khoom nyob rau hauv txoj kev ua kom tsis muaj menyuam, 0.2 µm sterile- qib lim feem ntau yog siv los tshem tawm cov kab mob thiab lwm yam kab mob microbial.